These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 32464709)

  • 1. Biogenic nanoparticles as immunomodulator for tumor treatment.
    Cheng K; Kang Q; Zhao X
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 Nov; 12(6):e1646. PubMed ID: 32464709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanovaccines for cancer immunotherapy.
    Zhang Y; Lin S; Wang XY; Zhu G
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 Sep; 11(5):e1559. PubMed ID: 31172659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of cancer-immunity cycle and tumor microenvironment by nanobiomaterials to enhance tumor immunotherapy.
    Yang J; Zhang C
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 Jul; 12(4):e1612. PubMed ID: 32114718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dendrimers for cancer immunotherapy: Avidity-based drug delivery vehicles for effective anti-tumor immune response.
    Rawding PA; Bu J; Wang J; Kim DW; Drelich AJ; Kim Y; Hong S
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2022 Mar; 14(2):e1752. PubMed ID: 34414690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanotechnology platforms for cancer immunotherapy.
    Yang Z; Ma Y; Zhao H; Yuan Y; Kim BYS
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 Mar; 12(2):e1590. PubMed ID: 31696664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining nanomedicine and immune checkpoint therapy for cancer immunotherapy.
    Boone CE; Wang L; Gautam A; Newton IG; Steinmetz NF
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2022 Jan; 14(1):e1739. PubMed ID: 34296535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in engineering local drug delivery systems for cancer immunotherapy.
    Abdou P; Wang Z; Chen Q; Chan A; Zhou DR; Gunadhi V; Gu Z
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 Sep; 12(5):e1632. PubMed ID: 32255276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved cancer immunotherapy strategies by nanomedicine.
    Guo S; Feng J; Li Z; Yang S; Qiu X; Xu Y; Shen Z
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2023; 15(3):e1873. PubMed ID: 36576112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell surface-nanoengineering for cancer targeting immunoregulation and precise immunotherapy.
    Wang Y; Huang G; Hou Q; Pan H; Cai L
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2023; 15(4):e1875. PubMed ID: 36567668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Instigation of the epoch of nanovaccines in cancer immunotherapy.
    Shah S; Famta P; Tiwari V; Kotha AK; Kashikar R; Chougule MB; Chung YH; Steinmetz NF; Uddin M; Singh SB; Srivastava S
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2023; 15(3):e1870. PubMed ID: 36410742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunoengineering with biomaterials for enhanced cancer immunotherapy.
    Xie YQ; Wei L; Tang L
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2018 Jul; 10(4):e1506. PubMed ID: 29333729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanomedicine approaches to improve cancer immunotherapy.
    Qiu H; Min Y; Rodgers Z; Zhang L; Wang AZ
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2017 Sep; 9(5):. PubMed ID: 28296286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging concepts in designing next-generation multifunctional nanomedicine for cancer treatment.
    Chakraborty K; Tripathi A; Mishra S; Mallick AM; Roy RS
    Biosci Rep; 2022 Jul; 42(7):. PubMed ID: 35638450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanoparticle-Based Nanomedicines to Promote Cancer Immunotherapy: Recent Advances and Future Directions.
    Liu J; Zhang R; Xu ZP
    Small; 2019 Aug; 15(32):e1900262. PubMed ID: 30908864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surface-engineered nanoparticles in cancer immune response and immunotherapy: Current status and future prospects.
    Chen J; Cong X
    Biomed Pharmacother; 2023 Jan; 157():113998. PubMed ID: 36399829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune checkpoint inhibition mediated with liposomal nanomedicine for cancer therapy.
    Ma GL; Lin WF
    Mil Med Res; 2023 Apr; 10(1):20. PubMed ID: 37106400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multifunctional plant virus nanoparticles: An emerging strategy for therapy of cancer.
    Azizi M; Shahgolzari M; Fathi-Karkan S; Ghasemi M; Samadian H
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2023; 15(6):e1872. PubMed ID: 36450366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combining Nanomedicine and Immunotherapy.
    Shi Y; Lammers T
    Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanomedicine in lung cancer: Current states of overcoming drug resistance and improving cancer immunotherapy.
    Wang W; Hao Y; Liu Y; Li R; Huang DB; Pan YY
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2021 Jan; 13(1):e1654. PubMed ID: 32700465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined cancer therapeutics-Tackling the complexity of the tumor microenvironment.
    Roma-Rodrigues C; Raposo LR; Valente R; Fernandes AR; Baptista PV
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2021 Sep; 13(5):e1704. PubMed ID: 33565269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.